BENEVIR BIOPHARM
BeneVir's immunotherapies for cancer are designed to induce the immune system to rid the body of two types of tumor cells: those currently responsible for cancer and those responsible for tumor recurrence and poor clinical outcomes. This is a unique approach in the emerging field of cancer immunotherapy.
BENEVIR BIOPHARM
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Gaithersburg, Maryland, United States
Country:
United States
Website Url:
http://www.benevirbiopharm.com
Total Employee:
1+
Status:
Active
Contact:
6465943703
Total Funding:
7 M USD
Technology used in webpage:
U.S. Server Location
Similar Organizations
Acublate
Acublate developing a HIFU device used to treat various types of solid tumors.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Foghorn Therapeutics
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
HelioWave Technologies
HelioWave Technologies is leveraging innovative microfluidic-based systems to revolutionize the way of sterility of biopharma products.
InCytu
InCytu develops anticancer immunotherapies that use the patient's own immune system to selectively target and destroy tumor cells.
Jounce Therapeutics
Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.
Marcadia Biotech
Marcadia Biotech is focused on developing therapeutic products to improve the daily life of people with diabetes and obesity.
PhyNet Dermatology LLC
PhyNet's mission is to bring together high-quality, collaborative dermatology practices and empower
Current Employees Featured
Ian Mohr Chair Of Scientific @ BeneVir Biopharm
Chair Of Scientific
Steven Fuhrmann VP of Research Operations @ BeneVir Biopharm
VP of Research Operations
2016-02-01
Founder
Official Site Inspections
http://www.benevirbiopharm.com
- Host name: ecbiz193.inmotionhosting.com
- IP address: 198.46.81.213
- Location: El Segundo United States
- Latitude: 33.9214
- Longitude: -118.413
- Metro Code: 803
- Timezone: America/Los_Angeles
- Postal: 90245
More informations about "BeneVir Biopharm"
BeneVir Biopharm - Crunchbase Company Profile
BeneVir Biopharm closed its last funding round on Nov 15, 2017 from a Debt Financing round. Who are BeneVir Biopharm 's competitors? Alternatives and …See details»
BeneVir Biopharm, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for BeneVir Biopharm, Inc. of Rockville, MD. Get the latest business insights from Dun & Bradstreet.See details»
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy …
May 2, 2018 T-Stealth™ Oncolytic Virus Platform Expected to Further Strengthen . Immunotherapy Platform and Capabilities . HORSHAM, PA, May 2, 2018 – Janssen Biotech, …See details»
BeneVir Biopharm, Inc. - LinkedIn
BeneVir Biopharm, Inc. | 481 followers on LinkedIn. ONCOLYTIC IMMUNOTHERAPY Immunotherapies are an exciting new class of therapies that utilize the immune system to attack and kill cancer cells.See details»
BeneVir Company Profile 2024: Valuation, Investors, Acquisition
Information on acquisition, funding, cap tables, investors, and executives for BeneVir. Use the PitchBook Platform to explore the full profile.See details»
BeneVir Biopharm - Products, Competitors, Financials, Employees ...
Headquarters Location. 1330 Piccard Drive Suite 101. Rockville, Maryland, 20850, United States. 240-474-5280See details»
BeneVir Biopharm - VentureRadar
BeneVir Biopharm Follow Following Location: USA. Founded in 2011. Privately Held " The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a …See details»
BENEVIR BIOPHARM, INC. - VentureRadar
BeneVir Biopharm is developing an oncolytic virus based on Herpes Simplex Virus-1 (HSV-1) that selectively targets and invades cancer cells, leaving normal cells intact. ... Dansk Biotek …See details»
Benevir Biopharm, Inc. - Golden
Benevir Biopharm, Inc. is a company founded in 2011 by Ian Mohr, Katherine Sacksteder and Matthew Mulvey. ... Organization. Company. Company attributes. Industry. Technology. …See details»
Johnson & Johnson Acquire BeneVir Biopharm - Drug Discovery …
May 2, 2018 Johnson & Johnson Acquire BeneVir Biopharm By HC2 Holdings, Inc. | May 2, 2018 HC2 Holdings, a diversified holding company, announced today that BeneVir Biopharm, …See details»
Johnson & Johnson pens $140M deal for preclinical …
May 2, 2018 Johnson & Johnson is paying $140 million upfront to buy oncolytic immunotherapy startup BeneVir Biopharm. The outlay gives J&J control of preclinical prospects designed to evade the body’s ...See details»
BeneVir Biopharm - Contacts, Employees, Board Members
Experience the new Crunchbase, powered by AI . Organization. BeneVir BiopharmSee details»
Montgomery County, Maryland-Based Benevir Biopharm, Inc. To …
May 8, 2018 BioHealth Innovation, Inc. (BHI) is a public private nonprofit organization focused on accelerating technology transfer and commercialization. BHI’s early stage company support …See details»
BeneVir Biopharm - VentureRadar
Find out more about BeneVir Biopharm, Healthtech, Bio Tech, Oncology, Biologics, Viral Technology and and . All; Ranked; Organisation Names; Apps and Links. Homepage (myVR) …See details»
Janssen to acquire BeneVir Biopharm for up to $1bn
Johnson & Johnson subsidiary Janssen Biotech has signed a definitive agreement to buy biotechnology company BeneVir Biopharm for a total consideration of $1.04bn. BeneVir is a …See details»
BeneVir Biopharm (USA) Funding: $7M - medicalstartups.org
Feb 26, 2025 The BeneVir oncolytic virus platform is based on T-StealthTM technology, which overcomes a major barrier to the clinical success of oncolytic viruses. This barrier is the body’s …See details»
J&J’s Janssen to Acquire BeneVir for $1 Billion - BioPharm …
May 9, 2018 Johnson & Johnson’s Janssen Biotech will acquire biotechnology company BeneVir Biopharm to strengthen Janssen’s immunotherapy platform. Janssen Biotech, part of Janssen …See details»
J&J snaps up oncolytic virus company BeneVir - BioPharma Dive
May 3, 2018 Dive Brief: Johnson & Johnson's pharma unit Janssen said Wednesday it will acquire private biotech BeneVir Biopharm in a deal potentially worth just over $1 billion, further …See details»
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy …
Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the …See details»
J&J pays $140m upfront for cancer-busting virus firm BeneVir
May 3, 2018 Johnson & Johnson’s initial push into immuno-oncology is gathering pace with an agreement to acquire BeneVir Biopharm and a portfolio of oncolytic viruses designed to infect …See details»